• MS-20 is a mixture of soybean fermentation metabolites which is produced in strictly controlled fermenter and with carefully chosen microorganisms that mimics the human intestinal environment.
  • The manufacturing and R&D procedures of Chemo young follow the international regulations.MS-20 was approved as the new drug by MOHW in 2011.
  • MS-20 can promote the growth of probiotics and act as an immunomodulator to improve immunity and inhibit tumor growth.
  • MS-20 is the first and the only oral new drug for ameliorating fatigue and appetite loss in patients receiving chemotherapy and thus improves the quality of life.
  • MS-20 is estimated to be approximately NT$4.5 billion in the Taiwan market, with an annual increase of 90,000 cancer patients. The number of cancer patients worldwide will reach 1.4 million, and medical needs will exceed $20 billion annually.